Uptake and user-base of Byooviz (Biogen) and Cimerli (Coherus) have both been low while general attitudes around biosimilars seem to
In the third annual patient chart analysis, major treatment shifts in biologic use and average daily steroid dose were observed.
Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and
Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s
Ferring Pharmaceutical’s achieved an innovative milestone in C.Diff treatment when it launched Rebyota, the first FDA approved Fecal Microbiota Transplant
New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 — The non-alcoholic
Online platform underscores Spherix’s commitment to innovation by providing dynamic solutions generated from the company’s comprehensive insights library of reports
Recent research suggests AbbVie has managed gastroenterologists’ concerns regarding JAK safety, setting up a potentially favorable encore in the Crohn’s
U.S. specialists’ lack of satisfaction with current treatment options in cutaneous and discoid lupus paves the way for advanced pharmacological
An FDA approval for Entyvio SC could exacerbate an already aggressive fight for second-line UC treatments. Exton, PA., May 4,
Genentech’s first campaign for eye drug Vabysmo is literally eye-opening. In the debut TV commercial, a woman opens an eye-shaped
Use of Trudhesa as an acute migraine treatment is on par with the more-established Reyvow, though future projections have it
